Urinary bladder, overactive Trials in Albuquerque, United States
Conditions / Urinary bladder, overactive / Albuquerque, United States
Urinary bladder, overactive has been the subject of sustained clinical investigation across multiple research sites.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01908829 | A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) | COMPLETED | PHASE3 |
| NCT00912964 | A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | COMPLETED | PHASE3 |
| NCT01972841 | This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder | COMPLETED | PHASE3 |
| NCT00454740 | Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder | COMPLETED | PHASE3 |
| NCT02045862 | A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder | COMPLETED | PHASE3 |
| NCT02386072 | A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) | COMPLETED | — |
| NCT00454896 | A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) | COMPLETED | PHASE3 |
| NCT00463541 | Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms | COMPLETED | PHASE3 |
| NCT00688688 | Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | COMPLETED | PHASE3 |
| NCT00662909 | A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | COMPLETED | PHASE3 |